BC Innovations | Aug 29, 2019
Distillery Therapeutics

Boosting cancer sensitivity to CDK4, CDK6 inhibitors by inhibiting the PRMT5-MDM4 axis

DISEASE CATEGORY: Cancer INDICATION: Melanoma; breast cancer; esophageal cancer; pancreatic cancer Inhibiting the PRMT5-MDM4 axis could increase the sensitivity of melanoma and other cancers to the dual CDK4/CDK6 inhibitor Ibrance palbociclib. In five human melanoma...
BC Innovations | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BC Extra | Jun 5, 2017
Financial News

Dova, Aileron seek NASDAQ listings

Oncology play Aileron Therapeutics Inc. (Cambridge, Mass.) and rare disease company Dova Pharmaceuticals Inc. (Durham, N.C.) each proposed IPOs on NASDAQ. Stapled peptide therapeutic company Aileron filed to raise $69 million in an offering underwritten...
BC Innovations | Apr 11, 2017
Distillery Techniques


TECHNOLOGY: SNPs SNPs on five genomic loci could help predict the risk of glioblastoma multiforme (GBM) and SNPs on eight genomic loci could help predict the risk of non-GBM glioma. Genome-wide association studies in 12,496...
BC Innovations | Dec 17, 2015
Distillery Therapeutics

Therapeutics: Mdm4 p53 binding protein homolog (MDM4; MDMX)

Cancer INDICATION: Cancer; lymphoma In vitro, patient sample and mouse studies suggest antisense oligonucleotides targeting MDM4 exon 6 could help treat cancer. Human melanoma, ovarian, breast, and other cancer cell lines and melanoma tumor samples...
BC Week In Review | Mar 2, 2015
Company News

Georgia State University, Cisen Pharmaceutical deal

Cisen and Georgia State partnered to develop a preclinical compound from the university to treat leukemia in China. The candidate inhibits the dimerization of mdm2 p53 binding protein homolog ( MDM2 ; HDM2 ) and MDM4 . The...
BC Week In Review | Mar 2, 2015
Clinical News

ALRN-6924: Phase I started

Aileron began a dose-escalation, U.S. Phase I trial to evaluate ALRN-6924 in 100-150 patients. Aileron Therapeutics Inc. , Cambridge, Mass.   Product: ALRN-6924   Business: Cancer   Molecular target: Mdm2 p53 binding protein homolog (MDM2) (HDM2)...
BC Extra | Nov 19, 2013
Financial News

Aileron raises $30 million series E

Aileron Therapeutics Inc. (Cambridge, Mass.) raised $30 million in a series E round. All of the company's existing investors participated, including Apple Tree Partners; Roche Venture Fund; Novartis Venture Funds; Lilly Ventures; SR One; and...
BC Week In Review | Nov 19, 2012
Clinical News

Aileron, Roche preclinical data

In in vivo and in vitro models of cancer, ATSP-7041 reactivated the p53-dependent pathway, induced p53-dependent apoptosis and inhibited cell proliferation. ATSP-7041 is a selective stapled peptide dual inhibitor of Mdm2 p53 binding protein homolog...
BioCentury | Sep 17, 2012
Product Development

Excited about cycling

New synthesis and screening technologies and the allure of access to previously undruggable targets are driving an explosion of new company formation and deal-making around macrocycles and constrained peptides. While it remains to be seen...
Items per page:
1 - 10 of 17